Introduction
Advanced breast cancer remains incurable. For these patients, durable responses and minimal toxicity are the main goals of current therapy. Prolongation of survival has been elusive.
The main feature distinguishing endocrine therapies has been their safety profile [1] [2] [3] [4] . The anti-oestrogen tamoxifen is the standard first endocrine therapy for postmenopausal women. When tamoxifen fails, either progestins or aromatase inhibitors are used [5, 6] . The main side effects of progestins are cardiovascular adverse events and weight gain [7] . Aminoglutethimide and formestane were the two commercially available aromatase inhibitors outside Japan (fadrozole being available only in Japan) until the recent introduction of anastrozole and letrozole [6, 8] . Aminoglutethimide (AG) is a nonsteroidal oral drug, with low specificity for the aromatase enzyme. Many patients receiving doses of 500 mg or more develop adrenal insufficiency and at these doses, it is accepted practice to prescribe corticosteroid supplementation. Formestane, which is administered parenterally, can produce local side effects.
Letrozole is a new, oral, highly selective, non-steroidal, competitive inhibitor of the aromatase enzyme [9] [10] [11] [12] . It is approximately 10,000 times as potent as AG in vivo, with no evidence of inhibition of progesterone or corticosterone at doses required to inhibit oestrogen synthesis [11] . In phase I clinical studies letrozole suppressed oestrone, oestradiol and oestrone sulphate by 75%-95% at once daily doses of 0.1-5 mg, with no clinically relevant effects on other hormones [12] [13] [14] [15] . In phase II studies, letrozole showed significant antitumour activity after failure of anti-oestrogens [14] [15] [16] [17] . Two doses were selected for further testing: 0.5 mg, which produced maximal suppression of plasma oestrogens, and 2.5 mg to investigate whether further increases in dose led to an enhancement of antitumour efficacy [18] . Both doses have been shown to have antitumour activity albeit with some suggestion in favour of the higher dose, particularly with respect to time to progression [19] . In one large randomised study comparing the efficacy and safety of letrozole at these two doses to megestrol acetate, letrozole 2.5 mg was more effective than letrozole 0.5 mg and more effective and better tolerated than megestrol acetate [20] .
We report here the results of a study comparing the efficacy and safety of letrozole 0.5 mg, letrozole 2.5 mg and aminoglutethimide in postmenopausal women with advanced breast cancer previously treated with antioestrogens.
Patients and methods

Patients
Postmenopausal women with histologically or cytologically confirmed breast cancer, positive or unknown oestrogen or progesterone receptors and measurable or evaluable advanced disease were eligible. Postmenopausal status was defined as no spontaneous menses for at least five years, or amenorrhoeic for at least 12 months and LH and FSH within the postmenopausal range for the laboratory, or amenorrhoeic for at least three months following bilateral oophorectomy or radiation castration. Oestrogen or progesterone receptors were considered positive if any assay of primary or secondary tumour tissue was positive by the laboratory. Receptors were considered unknown if no assay was known to be positive or negative. Patients had either relapsed on adjuvant therapy (given for > 6 months) or within 12 months from discontinuation, or had progressed during anti-oestrogen treatment for metastatic disease. Adjuvant chemotherapy and/or one chemotherapy regimen for advanced disease was allowed Eligible patients had WHO performance status ^ 2, and haematology and serum chemistry within normal limits.
Important exclusion criteria were: CNS involvement, lymphangitis carcinomatosa of the lungs, inflammatory breast cancer, hepatic metastases involving more than one third of the liver; concurrent or previous malignant disease; uncontrolled cardiac disease or diabetes melhtus; adrenal disease; porphyria; confirmed peptic ulceration.
The study was approved by the local Ethics Review Boards and the Freiburger Ethik Kommission International and all patients gave written consent to participate.
Study design
This was a multicentre (86 centres in 11 countries), open-label, randomised, comparative trial conducted according to Good Clinical Practice requirements. Treatments were randomly assigned 1:1:1, letrozole 2.5 mg once daily, letrozole 0.5 mg once daily or aminoglutethimide 250 mg twice daily. Patients treated with AG received daily oral glucocorticoid supplementation (hydrocortisone 30 mg or cortisone acetate 37.5 mg).
Patients were staged at baseline and assessed at three monthly intervals until disease progression and thereafter followed for survival. The primary analysis for response, time to progression, time to failure and safety was performed nine months after the last patient was enrolled, or 33 months after initiation of the study [21] , The primary analysis of overall survival took place 39 months after study initiation [22] . This paper reports the results of an updated analysis with data for up to 45 months after initiation, to provide more mature estimates of duration of overall tumour response and duration of clinical benefit. Six-monthly updates of overall survival were planned until 90% of patients died but no further analysis of tumour variables was planned beyond 45 months.
Measurement of superficial or palpable lesions, chest X-ray, routine haematology and chemistry, adverse events and physical examination including weight were recorded at each visit. ECG was performed at baseline and at three and 12 months.
Bone scan and/or skeletal survey, liver ultrasound or CTscan were performed at baseline and at six months, or every three months if positive at baseline.
The primary endpoint was overall objective tumour response (complete response, CR, plus partial response, PR). Duration of response, time to progression, time to treatment failure, and time to death were secondary endpoints. Objective tumour response was assessed using UICC criteria [23] and maximal tumor shrinkage had to be observed on at least two occasions at least four weeks apart (in practice, response was confirmed at the next scheduled visit, three months later). Stable disease had to last at least six months before being counted as such. Lesions considered non-evaluable, non-measurable were: osteoblastic lesions, mixed blastic/lytic bone lesions at the same site, pleural effusion, ascites, hilar enlargement. Response in non-evaluable, nonmeasurable lesions could only be categorised as PD or complete disappearance. Definitive assessment of tumour response and progression of disease was provided by an external, independent, treatmentblinded peer review committee (two medical oncologists and one radiologist for each participating country). Time to progression (TTP) was defined as time from randomisation to progression or cancerrelated death or death from unknown cause during therapy. Time to failure (TTF) was time to diagnosis of progression, discontinuation of therapy, death, or any other cause, whichever event occurred earliest.
Soft tissue disease was considered the dominant site when the only site involved. Bone was considered dominant if present as the only site or if accompanied by soft tissue lesions. Visceral was considered dominant whenever present.
Safety and tolerability were assessed using the NCI Common Toxicity Criteria (CTC) and by routine haematology and serum chemistry.
Statistical methodology
A sample size of 540 patients (146 per treatment arm plus 23% increase to allow for loss to follow-up and non-evaluability of response) was calculated as necessary to detect with 90% power at the 5% (twosided) significance level a difference between treatments of > 15% in objective tumour response, assuming a minimum response rate of 10%. The sample size allowed a ratio of 1.5 in hazard rates for TTP to be detected as significant at the 5% level with 90% power, assuming a median TTP of five months [24] .
Overall objective tumour response was analysed by logistic regression (odds ratios). Time to events data (TTP, TTF, duration of response, duration of clinical benefit and time to death, TTD) were analysed using Cox proportional hazards regression models (risk ratios). Estimates of median times were obtained by the Kaplan-Meier productlimit method.
All analyses were performed on the modified intent-to-treat population which included all patients enrolled and who received any study medication. Analyses of overall response. TTP. TTF and overall survival were adjusted for baseline covariates (age, disease free interval, hormone receptor status, dominant site of disease, extent of disease, performance status, prior chemotherapy, use of and response to previous anti-oestrogen therapy and body mass index). Unadjusted analyses were conducted for confirmatory purposes, but adjusted comparisons were pre-specified as primary. No adjustments of Pvalues were made for multiple comparisons or for multiple endpoints. The main comparison of interest was 2.5 mg letrozole vs. aminoglutethimide.
The safety analysis was descriptive. Certain expected adverse expe- (72) '" Dominant site and number of anatomical sites do not sum to 100 % as peer review considered that some patients did not have evidence of malignant disease at baseline or baseline images were insufficient to assess extent of disease b When patient had received only adjuvant anti-oestrogen therapy, or when metastatic lesion had been surgically excised or irradiated and response could not be ascertained.
riences such as rash, somnolence, and nausea were compared using Clopper-Pearson exact 95% CIs for the difference between the worse letrozole dose (i.e., higher incidence) and aminoglutethimide.
Results
Patients
Over two years 555 women were enrolled and received therapy (letrozole 2.5 mg n = 185, letrozole 0.5 mg n = 192, aminoglutethimide n = 178). There were no major differences amongst the three treatment groups in baseline characteristics ( Table 2 ). These differences were not significant although there was a trend favouring letrozole 2.5 mg over AG (odds Baseline covariates with a significant influence on objective tumour response were: disease free interval, performance status, dominant site of disease, and prior chemotherapy (Table 3) . Response rates were highest for women with predominantly soft tissue disease, regardless of trial treatment. Letrozole 2.5 mg produced higher response rates in patients with predominantly bone (17%) and visceral (17%) involvement compared to aminoglutethimide (9% for bone, 3% for visceral disease). Response rates for letrozole in patients who had relapsed during adjuvant anti-oestrogen therapy were 18% with letrozole 0.5 mg, 19% with letrozole 2.5 mg and 9% for aminoglutethimide. Among women refractory to antioestrogen therapy for advanced disease, responses were 17% for letrozole 2.5 mg, 16% for letrozole 0.5 mg and 9% for aminoglutethimide.
Duration of objective response and stabilisation of disease
Median duration of objective tumour response was 24 months for letrozole 2.5 mg, 21 months for letrozole 0.5 mg and 15 months for aminoglutethimide. Objective response lasted at least eight months in all responding patients.
Median duration of objective response and stable disease lasting at least six months ('clinical benefit') was 21 months for letrozole 2.5 mg, 18 months for letrozole 0.5 mg and 14 months for aminoglutethimide.
Time to progression (TTP)
At analysis, 148 patients (80%) in the letrozole 2.5 mg treatment arm had progressed, similar to 162 (84%) on letrozole 0.5 mg and 147 (83%) on aminoglutethimide. Figure 1 plots TTR Cox regression indicated significant superiority of the higher dose of letrozole over aminoglutethimide (2.5 mg: AG risk ratio (RR): 0.72, 95% CI: 0.57-0.92, P -0.008). The unadjusted analysis gave similar results (RR: 0.79, P -0.05). The difference between the two doses of letrozole was not statistically significant (P -0.3). Median TTP was similar in all three treatment arms at a little over three months. Denominator is the number of patients in class of covariate at baseline (see Table 1 ). 
Time to treatment failure (TTF)
Treatment with letrozole 2.5 mg led to fewer failures (151 patients, 82%) than with letrozole 0.5 mg (172 patients, 90%) or aminoglutethimide (158 patients, 89%).
Analysis of time to treatment failure (Cox regression) showed significant superiority of the higher letrozole dose over aminoglutethimide (2.5 gave similar results (RR: 0.75, P -0.01). There was no significant difference in TTF between the two letrozole doses (P -0.2). Median TTF was similar in the three treatment arms (at just over three months), and closely similar to TTP.
Overall survival
At analysis, around 60% of enrolled patients had died. There were significantly fewer deaths in the letrozole 2.5 mg arm (98 patients, 53%) than in the aminoglutethimide arm (123 patients, 69%). In the letrozole 0.5 mg arm, 60% of enrolled patients (115) had died. Figure 2 plots overall survival. Letrozole 2.5 mg was significantly superior to aminoglutethimide (RR: 0.64, 95% Cl: 0.49-0.85, P = 0.002) and to letrozole 0.5 mg (RR: 0.74, 95% Cl: 0.56-0.98, P = 0.04). There was no significant difference between letrozole 0.5 mg and aminoglutethimide (RR 0.86, . Median time to death was longer for letrozole 2.5 mg (28 months) compared with letrozole 0.5 mg (21 months) and aminoglutethimide (20 months).
Tolerability and safety
A similar percentage of patients in each group reported adverse events regardless of relationship to study treatment (76% for letrozole 2.5 mg, 75% for letrozole 0.5 mg, 71% for aminoglutethimide). However, significantly more patients on AG (81 patients, 46%) experienced adverse events considered by the investigator to be drugrelated compared with letrozole 2.5 mg (61 patients, 33%) and letrozole 0.5 mg (55 patients, 29%, chi-squared test). Table 4 shows the most frequent drug-related adverse events. Nausea was the commonest drug-related adverse event for letrozole (2.5 mg, 10%; 0.5 mg, 7%; AG, 10%). Rash (composite term) was the most frequent drug-related adverse event reported for aminoglutethimide (11%) and occurred more frequently than with letrozole (2.5 mg, 3%; 0.5 mg, 1%). Only hot flushes and fatigue were reported slightly more frequently with letrozole 2.5 mg than with the other two treatments. Five (2.8%) patients on aminoglutethimide experienced serious treatment-related adverse events (one case each of postural hypotension, malaise, whole body erythema, confusion, acute renal insufficiency) compared with one patient (0.5%) on letrozole 0.5 mg (deep vein thrombosis) and no patients on letrozole 2.5 mg.
No clinically relevant differences between treatments were seen with respect to blood pressure, pulse, body weight or laboratory measurements.
Discussion
We compared the efficacy, safety and tolerability of a new aromatase inhibitor, letrozole, with an established aromatase inhibitor, aminoglutethimide, in women with advanced breast cancer after failure of anti-oestrogens.
The data show superior anti-tumour efficacy of letrozole compared with aminoglutethimide. At the dose of 2.5 mg letrozole was statistically significantly superior to AG in overall survival, duration of clinical benefit, time to progression and time to treatment failure. For overall survival the effect in favour of letrozole 2.5 mg (RR: 0.64) corresponds to a 36% reduction in the risk of death compared with aminoglutethimide. The dose of 2.5 mg was also statistically significantly superior to the dose of 0.5 mg in overall survival. The lower letrozole dose was consistently intermediate in effect to letrozole and AG, but was not significantly better than AG. The consistency between the adjusted and the unadjusted analyses supports the reliability of the results.
In breast cancer disease stabilisation is considered comparable to objective response [25] [26] [27] . In the present study there was little difference between treatments in the number of patients who achieved a complete or partial response or disease stabilisation. However, the duration of clinical benefit was significantly longer for the patients who received letrozole 2.5 mg than for patients on aminoglutethimide.
The response rate seen with aminoglutethimide is at the low end of the range reported in the literature. This is unlikely to be explained by the dose used. Studies comparing aminoglutethimide 500 mg and 1000 mg daily have concluded that the two doses have similar efficacy but that 500 mg daily has advantages in terms of safety and better tolerability [28] [29] [30] . The relatively low response observed could be explained by the relatively high proportion of patients with visceral disease (Table 1) , in whom aminoglutethimide produced a very low response rate.
The superiority of letrozole over another established endocrine therapy is in contrast to several previous reports which have suggested that there is no major difference in efficacy between the established endocrine therapies (the anti-oestrogen tamoxifen, progestins and the aromatase inhibitors aminoglutethimide and formestane) [1] [2] [3] [4] [31] [32] [33] [34] . However, letrozole belongs to a new generation of aromatase inhibitors which are able to suppress plasma levels of oestrogens by more than 95% and in vivo aromatisation by 97% to 99% [35, 36] . Another of these new potent oral aromatase inhibitors, vorozole, has also been compared to aminoglutethimide and has produced a significantly higher frequency of clinical benefit and a significantly longer time to treatment failure compared to aminoglutethimide, although time to progression and survival were not affected [37] . Three of these new aromatase inhibitors, letrozole, vorozole and anastrozole, have been prospectively compared to megestrol acetate after failure of anti-oestrogens. Letrozole 2.5 mg showed a significantly higher response rate, duration of response and of clinical benefit and superior time to treatment failure compared to the progestin [20] . Anastrozole 1 mg and 10 mg were comparable to megestrol acetate in all efficacy parameters in two randomised trials [38] [39] [40] . A significant survival advantage over the progestin was demonstrated for the lower dose of anastrozole when the two trials were pooled, although other efficacy parameters were not affected, and the survival benefit for the higher dose was not statistically significant [41] . When vorozole at the dose of 2.5 mg was compared to megestrol acetate, no statistically significant differences were observed in efficacy [42] . These recent data suggest that letrozole is the only one of these new aromatase inhibitors which has consistently shown significant improvements in antitumor efficacy over two existing standard endocrine therapies.
The significant survival advantage of the 2.5 mg letrozole dose compared to the lower letrozole dose indicates that the higher dose is more active. Both doses, however, produce similar suppression of circulating oestrogens and similar in vivo inhibition of aromatisation of androstenedione to oestrone [18] . A dose effect has rarely been observed with endocrine anticancer therapies [28, 43, 44] . However, clinical superiority of 2.5 mg letrozole compared to 0.5 mg was observed in another study [20] in terms of response, time to progression, time to treatment failure and overall survival. The superiority of the higher dose could be due to a greater inhibition of intratumoural aromatase activity. A recent report describes dose dependent inhibition of tumour growth in an in vivo model of intratumoural aromatase [45] . It could also be that the present methods for detecting circulating oestrogens are not sufficiently sensitive to discriminate differences in profound suppression.
The data show that letrozole is better tolerated than aminoglutethimide. Expected adverse experiences of aminoglutethimide (rash and somnolence) and the transient nausea associated with letrozole were observed in the study.
In summary, the data shown support letrozole 2.5 mg to be superior to aminoglutethimide in antitumour efficacy with improved tolerability. Letrozole 2.5 mg offers an important addition to the treatment of advanced breast cancer after anti-oestrogen therapy fails and represents a preferred alternative over aminoglutethimide.
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